Pharmacogenetics of antipsychotics: recent progress and methodological issues

Introduction: Antipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects. Pharmacogenetics provides a valuable tool to fulfill the promise of personalized medicine by tailoring treatment based on one's genetic markers. Areas covered: This article reviews the recent progress in pharmacogenetic research of antipsychotic drugs since 2010, focusing on two areas: antipsychotic-induced weight gain and clozapine-induced agranulocytosis. The article also provides discussion on the important methodological issues in this area of research. The specific aim of this article is to provide the reader with up-to-date evidence in pharmacogenetic research, and for them to gain familiarity to the issues and challenges facing the field. Expert opinion: Pharmacogenetic studies of antipsychotic drugs are promising despite many challenges. Recent advances as reviewed in this article push the field closer to routine clinical utilization of pharmacogenetic testing. Progress in genomic technology and bioinformatics, larger sample sizes, better phenotype characterization, and careful consideration of study design issues will help to elevate antipsychotic pharmacogenetics to its next level.

[1]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[2]  Young-Min Park,et al.  G-protein β3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients , 2009, Psychiatry investigation.

[3]  H. Dunford,et al.  Oxidation of clozapine and ascorbate by myeloperoxidase. , 1999, Archives of biochemistry and biophysics.

[4]  A. Malhotra,et al.  DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. , 2010, Pharmacogenetics and genomics.

[5]  I. Roots,et al.  Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. , 2001, Pharmacogenetics.

[6]  J. Kane,et al.  Optimizing pharmacologic treatment of psychotic disorders , 2003 .

[7]  H. Meltzer,et al.  759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. , 2002, Lancet.

[8]  F. Claas,et al.  No Direct Clinical Relevance of the Human Leucocyte Antigen (HLA) System in Clozapine-Induced Agranulocytosis , 1992, Drug safety.

[9]  J. Kane,et al.  The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. , 2003, The Journal of clinical psychiatry.

[10]  S. Tsai,et al.  Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment , 2010, Pharmacogenetics and genomics.

[11]  J. Lieberman,et al.  Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. , 1997, Blood.

[12]  B. Lerer,et al.  An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. , 1998, The international journal of neuropsychopharmacology.

[13]  A. Malhotra,et al.  Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. , 2011, The Journal of clinical psychiatry.

[14]  P. Weiden,et al.  The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. , 2009, The Journal of clinical psychiatry.

[15]  J. Hebebrand,et al.  Lack of association between the –759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals , 2004, Psychiatric genetics.

[16]  L. Khaodhiar,et al.  Metabolic syndrome with the atypical antipsychotics. , 2010, Current opinion in endocrinology, diabetes, and obesity.

[17]  Anil K. Malhotra,et al.  Genomics and the future of pharmacotherapy in psychiatry , 2007, International review of psychiatry.

[18]  D. Allison,et al.  The search for human obesity genes. , 1998, Science.

[19]  G. Reynolds,et al.  Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism , 2002, The Lancet.

[20]  J. Lieberman,et al.  HLA associations in clozapine-induced agranulocytosis. , 1995, Blood.

[21]  G. Muscettola,et al.  Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[23]  A. Malhotra,et al.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction , 2011, Expert opinion on drug metabolism & toxicology.

[24]  I. Roots,et al.  Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. , 2001, Archives of general psychiatry.

[25]  Del D. Miller,et al.  Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[26]  Abraham Weizman,et al.  HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. , 1998, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[27]  B. Godlewska,et al.  Olanzapine-induced weight gain is associated with the −759C/T and −697G/C polymorphisms of the HTR2C gene , 2009, The Pharmacogenomics Journal.

[28]  Jung-Eun Choi,et al.  Lack of association between the −759C/T polymorphism of the 5‐HT2C receptor gene and olanzapine‐induced weight gain among Korean schizophrenic patients , 2008, Journal of clinical pharmacy and therapeutics.

[29]  Peilin Jia,et al.  Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs , 2010, Molecular Psychiatry.

[30]  J. Lieberman,et al.  Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.

[31]  M. Morrell,et al.  The Expert Consensus Guideline Series Treatment of Epilepsy , 2001, Epilepsy & Behavior.

[32]  G. Currier,et al.  Introduction: Methods, Commentary, and Summary , 2005 .

[33]  S. Tsai,et al.  −759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain , 2002, The Lancet.

[34]  A. Malhotra,et al.  D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. , 2010, The American journal of psychiatry.

[35]  J. Lieberman,et al.  Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. , 2010, Pharmacogenomics.

[36]  W. Dubin,et al.  Medication Adherence: A Review of the Literature and Implications for Clinical Practice , 2009, Journal of psychiatric practice.

[37]  J. Lieberman,et al.  HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. , 1990, Archives of general psychiatry.

[38]  Pall I. Olason,et al.  Common variants conferring risk of schizophrenia , 2009, Nature.

[39]  Michael Dettling,et al.  Impact of Myeloperoxidase and NADPH-Oxidase Polymorphisms in Drug-Induced Agranulocytosis , 2004, Journal of clinical psychopharmacology.

[40]  J. Lieberman,et al.  Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain , 2010, The Pharmacogenomics Journal.

[41]  J. Kennedy,et al.  Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications , 2012, Molecular Psychiatry.

[42]  K. Hong,et al.  −759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[43]  J. Schein,et al.  Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. , 1998, The Journal of clinical psychiatry.

[44]  Abraham Weizman,et al.  NQO2 gene is associated with clozapine-induced agranulocytosis. , 2003, Tissue Antigens.

[45]  H. Meltzer,et al.  Treatment-resistant schizophrenia--the role of clozapine. , 1997, Current medical research and opinion.

[46]  H. Meltzer,et al.  −759C/genetic variation of 5HT2C receptor and clozapine-induced weight gain , 2002, The Lancet.

[47]  Gregory E Simon,et al.  Personalized medicine for depression: can we match patients with treatments? , 2010, The American journal of psychiatry.

[48]  Paul W. Franks,et al.  Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden , 2009, Human molecular genetics.

[49]  Annette Lee,et al.  Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. , 2012, Archives of general psychiatry.

[50]  I. Cascorbi,et al.  Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens , 2007, The Pharmacogenomics Journal.

[51]  J. Lieberman,et al.  The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. , 1995, Blood.

[52]  A. Malhotra,et al.  Pharmacogenetics of antipsychotic-induced weight gain , 2004, Psychopharmacology.

[53]  Del D. Miller,et al.  Clozapine‐induced weight gain associated with the 5HT2C receptor −759C/T polymorphism , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[54]  T. Lencz,et al.  Pharmacogenetics in psychiatry: translating research into clinical practice , 2012, Molecular Psychiatry.

[55]  I. Cascorbi,et al.  Drug-Induced Agranulocytosis: Impact of Different Fcγ Receptor Polymorphisms? , 2005, Journal of clinical psychopharmacology.

[56]  J. Brockmöller,et al.  Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. , 2000, Pharmacopsychiatry.

[57]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[58]  Jürgen Brockmöller,et al.  Pharmacogenetics-based therapeutic recommendations — ready for clinical practice? , 2005, Nature Reviews Drug Discovery.

[59]  G. Reynolds,et al.  Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis , 2005, Pharmacogenetics and genomics.

[60]  J. Kaprio,et al.  The heritability of body mass index among an international sample of monozygotic twins reared apart. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[61]  A. Convit,et al.  Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders: Results From a 12-month, Real-World Study , 2012, Journal of clinical psychopharmacology.

[62]  A. Malhotra,et al.  Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. , 2009, The Journal of clinical psychiatry.